The four glycoforms of the cellular prion protein (PrP C ) variably glycosylated at the two N-linked glycosylation sites are converted into their pathological forms (PrP Sc ) in most cases of sporadic prion diseases. However, a prominent molecular characteristic of PrP Sc in the recently identified variably protease-sensitive prionopathy (VPSPr) is the absence of a diglycosylated form, also notable in familial Creutzfeldt-Jakob disease (fCJD), which is linked to mutations in PrP either from Val to Ile at residue 180 (fCJD V180I ) or from Thr to Ala at residue 183 (fCJD T183A ). Here we report that fCJD V180I , but not fCJD T183A , exhibits a proteinase K (PK)-resistant PrP (PrP res ) that is markedly similar to that observed in VPSPr, which exhibits a five-step ladder-like electrophoretic profile, a molecular hallmark of VPSPr. Remarkably, the absence of the diglycosylated PrP res species in both fCJD V180I and VPSPr is likewise attributable to the absence of PrP res glycosylated at the first N-linked glycosylation site at residue 181, as in fCJD T183A . In contrast to fCJD T183A , both VPSPr and fCJD V180I exhibit glycosylation at residue 181 on di-and monoglycosylated (mono181) PrP prior to PK-treatment. Furthermore, PrP V180I with a typical glycoform profile from cultured cells generates detectable PrP res that also contains the diglycosylated PrP in addition to mono-and unglycosylated forms upon PK-treatment. Taken together, our current in vivo and in vitro studies indicate that sporadic VPSPr and familial CJD V180I share a unique glycoform-selective prion formation pathway in which the conversion of diglycosylated and mono181 PrP C to PrP Sc is inhibited, probably by a dominant-negative effect, or by other co-factors.
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Introduction
Prion diseases are a group of fatal transmissible spongiform encephalopathies affecting both animals and humans. Human prion diseases are highly heterogeneous: They can be inherited, sporadic, or acquired, and include various forms of CreutzfeldtJakob disease (CJD), Gerstmann-Strä ussler-Scheinker (GSS) disease, fatal insomnia, and kuru. Moreover, regardless of differences in phenotypes, they are all caused by infectious pathologic prions (PrP Sc ) that are derived from the cellular prion protein (PrP C ) through a conformational transition [1] . The partially proteinase K (PK)-resistant PrP27-30 (PrP res ) is the molecular hallmark of all human prion diseases. On Western blots three major PrP bands are typically observed but composed of a di-, two mono-, and an unglycosylated PrP glycoforms because the two individually monoglycosylated PrP at asparagine residues N181 and N197 partially overlap. There are a few exceptions [2] [3] [4] [5] . Of them, all but one are associated generally with PrP mutations showing different PrP banding patterns, as in GSS and familial CJD. GSS is characterized by the presence of additional small PK-resistant PrP fragments, whereas fCJD linked to either PrP T183A or PrP V180I mutations exhibits a PrP res that lacks the diglycosylated PrP species [2] [3] [4] .
The abnormal PrP associated with the recently identified prion disease termed variably protease-sensitive prionopathy (VPSPr) has highly distinctive features [6, 7] , including a one that was initially reported as an atypical sCJD by Giaccone et al [8] . Although there is no PrP mutation in the open reading frame of the PrP gene, VPSPr is associated with a PrP res that bears three of the characteristics of inherited rather than sporadic prion diseases. First, the diglycosylated PrP Sc in VPSPr is virtually undetectable, as it is also with PrP res in fCJD V180I and fCJD T183A [3, 4, 7] . Second, VPSPr is characterized by the presence in the brain of more than three PrP res fragments including a ,7 kDa fragment, a characteristic of GSS [2, 7] . However, in marked contrast to PrP res in GSS, PrP res in VPSPr is preferentially detected with the 1E4 antibody instead of the widely used 3F4 antibody, forming a pathognomonic five-step ladder-like PrP electrophoretic profile [7] . Finally, in some VPSPr cases, a positive family history of cognitive impairment was observed [6, 7] . Clearly, the PrP Sc associated with VPSPr is distinct from the prion strains associated with other sporadic prion diseases. The molecular mechanism underlying the formation of the peculiar prion in VPSPr has yet to be determined.
Compared to PrP in the most common sporadic CJD (sCJD), a significant decrease in the ratio of diglycosylated PrP to monoglycosylated PrP treated with or without PK was reported in fCJD T183A previously [3] . This is because the T183A PrP mutation completely abolishes the first N-linked glycosylation site at residue 181 (N181) [9] [10] [11] and the detected diglycosylated PrP is derived only from wild-type PrP (3, the current study). In contrast, the PrP glycoforms in VPSPr appear typical prior to PKtreatment; however, there is no detectable diglycosylated PrP Sc after PK-treatment. As with VPSPr, the molecular mechanism underlying the absence of the diglycosylated PrP in fCJD V180I is unclear [4] . Using a combination of in vivo and in vitro assays, our current study indicates that the absence of the diglycosylated PrP Sc in both VPSPr and fCJD V180I results from a glycoform-selective prion formation pathway associated with the inability of the diand mono-glycosylated PrP C at N181 to convert into PrP Sc in the brain.
Results

Both inherited CJD
V180I and sporadic VPSPr exhibit no diglycosylated PrP res In contrast to sCJD, both fCJD V180I and VPSPr exhibit monoand un-glycosylated PK-resistant PrP bands but virtually no diglycosylated PrP when probed with the 3F4 antibody (Fig. 1A) . However, in the samples that were not treated with PK (Fig. 1B) , diglycosylated PrP was readily detectable not only in sCJD and non-CJD but also in fCJD V180I and VPSPr. The fCJD T183A exhibited a very faint diglycosylated PrP band that was visible in over-exposed blots and is from the wild-type allele as reported previously [3] .
Lack of diglycosylated PrP res is attributable to loss of glycosylation at the first N-linked glycosylation site in fCJD V180I and VPSPr
To investigate whether and how the two individual N181 and N197 sites are associated with the lack of the diglycosylated PrP res in fCJD V180I and VPSPr, we probed PrP treated with PK or PK plus PNGase F using V14 and Bar209 antibodies that have been demonstrated to distinguish mono181 and mono197 but not diand unglycosylated PrP (Fig. S1 and S2 ) [11] [12] [13] [14] . On the blot probed with the Bar209 antibody that specifically detects mono197, both mono197 and unglycosylated PrP migrating at ,26-28 kDa and ,19-20 kDa, respectively, were detected in all samples treated with PK alone except for fCJD T183A that had a significantly under-represented unglycosylated PrP ( Fig. 2A) . fCJD T183A exhibited a dominant PrP band migrating at ,26-28 kDa, corresponding to mono197. In the samples treated with PK plus PNGase F, only one PrP band migrating at ,19-20 kDa was observed, corresponding to un-and deglycosylated PrP species ( Fig. 2A) . Therefore, mono197 is converted into PrP res in the four prion diseases examined.
On the blot probed with the V14 antibody that specifically detects mono181 [11, 12] , the PrP band migrating at ,24-26 kDa corresponding to mono181 was detected in sCJD in addition to the band migrating at ,19-20 kDa corresponding to the unglycosylated PrP (Fig. 2B) . In contrast, as in fCJD T183A , no mono181 was detected in both fCJD V180I and VPSPr, while the unglycosylated PrP migrating at ,19-20 kDa was detected in all diseases (Fig.  2B) . Only the faint under-represented unglycosylated PrP band migrating at ,19-20 kDa was detected in fCJD T183A . After treatment with PK plus PNGase F, the un-/de-glycosylated PrP band migrating at ,19-20 kDa was detected in all cases examined (Fig. 2B) . These results suggest that the lack of diglycosylated PrP res in both VPSPr and fCJD V180I is associated with the absence of the PK-resistant mono181 as found in fCJD
T183A
. Notably, the migration of PrP res from VPSPr-129MV and fCJD V180I was slightly slower than that of PrP res from sCJD type 2, VPSPr-129MM and fCJD T183A when probed with V14 and Bar209 [ Fig.  2A and 2B], although it was very similar when probed with 3F4 (Fig. 1A) . What is responsible for the discrepancy in the migration of the core PrP res observed when probing with these antibodies remains to be determined in the future. To investigate whether there are any changes in the two monoglycosylated PrP species in the samples prior to PKtreatment, we examined PrP profiles from VPSPr and fCJD V180I with the two antibodies in untreated samples. In contrast with PKtreated PrP, mono181 or mono197 was detected in both VPSPr and fCJD V180I in addition to C2 and C1, two fragments identified previously in human brains [11, 15] , similar to those detected in the sCJD control (Fig. 2C) . Thus, in contrast to fCJD T183A , both VPSPr and fCJD V180I were found to contain mono181 before PKtreatment. In combination these data suggests that mono181 is not converted into PrP res in the two diseases and that mono181 of VPSPr and fCJD V180I is different from that of sCJD. Notably, mono197 from all conditions migrated more slowly than did mono181 at ,0.5-1 kDa, consistent with previous observations [11, 12] . Moreover, the ratio of mono197 intensity to unglycosylated PrP was significantly greater than that of mono181 to unglycosylated PrP in all three diseases (sCJD: 0.92 6 0.02 vs. 0.43 6 0.08, p , 0.001; VPSPr: 0.81 6 0. 02 vs. 0.48 6 0.04, p , 0.001; and fCJD V180I : 1.17 6 0.01 vs. 0.38 6 0.04, p , 0.001) ( Fig. 2C and 2D) . Therefore, the lack of diglycosylated PrP res in fCJD V180I and VPSPr is directly attributable to the absence of PKresistant mono181, whereas prior to PK-treatment the proportions of diglycosylated PrP and mono181 do not appear unusual in the two diseases.
Neither PK-resistant nor PK-sensitive PrP Sc glycosylated at N181 is detected in both VPSPr and fCJD
V180I
To determine whether there is a PK-sensitive mono181 PrP Sc in both VPSPr and fCJD V180I , we isolated total PrP Sc using the gene 5 protein (g5p) that has proven to specifically capture not only PKresistant but also PK-sensitive PrP Sc [6, 16] . The PrP Sc captured by g5p was untreated or treated with PK prior to Western blotting and probing with Bar209 or V14. The Bar209 antibody detected three PrP bands in untreated sCJD sample corresponding to mono197 and unglycosylated full-length PrP (Un-) as well as the endogenously N-terminally truncated PrP fragment called C2, respectively (Fig. 3A) . After PK-treatment, PK-resistant mono197 and unglycosylated PrP were observed (Fig. 3A) . Similar to sCJD, both VPSPr and fCJD V180I also exhibited three PrP bands prior to PK-treatment ( Fig. 3B ), while the PK-resistant mono197 and unglycosylated fragments appeared upon PK-treatment when probed with Bar209 (Fig. 3B ).
When probed with the V14 antibody, mono181, unglycosylated full-length PrP and C2, respectively, were detected in untreated sCJD samples (Fig. 3C) . The PK-resistant mono181 and unglycosylated PrP were observed in PK-treated sCJD samples as well. In contrast, mono181 was not detectable in either untreated or PK-treated samples from VPSPr and fCJD V180I with V14 (Fig. 3D) . Therefore, neither PK-resistant nor PK-sensitive PrP Sc glycosylated at residue 181 is detectable in either VPSPr or fCJD V180I .
PrP res from fCJD V180I reveals an electrophoretic profile similar to that of VPSPr
When probed with 3F4, PrP
Sc from all six fCJD V180I cases treated with different amounts of PK exhibited two bands corresponding to mono-and un-glycosylated PrP res and no diglycosylated PrP res ( Fig. 4A and 4C) , the same as VPSPr-129MM [7] . Moreover, like VPSPr, all cases exhibited the five bands producing a ladder-like electrophoretic profile (LLEP) when probed with 1E4, including a predominant 1E4-preferentiallydetectable 7 kDa fragment ( Fig. 4B and 4D ). PrP Sc from fCJD V180I revealed a higher affinity for 1E4 than for 3F4 ( Fig  4A through 4D) , another molecular feature of PrP Sc observed in VPSPr. When the PK-treated PrP Sc from the two diseases is compared side by side on the gel, they exhibited virtually identical migration patterns that are different from those of sCJD (Fig. 4E ).
Glycan composition in VPSPr and fCJD V180I is different from that in sCJD
The finding that di-and mono-glycosylated PrP species carrying glycans at N181 are unable to form PrP Sc may suggest that the glycan composition at this site in VPSPr and fCJD V180I is different from that in sCJD. Thus, we compared the binding of ricinus communis agglutinin I (RCA-I) to PrP glycans. RCA-I recognizes oligosaccharides ending in galactose/N-acetylgalactosamine (Galb1-4GlcNAcb1-R) and has previously been used to compare the differences in glycan composition in different species and prion strains [17] . RCA-I reacted with both di-and mono-glycosylated PrP (Fig. S3A) (Fig. S3B ). This result indicates that glycan composition in VPSPr and fCJD V180I is indeed different from that in sCJD by an increased amount of Galb1-4GlcNAcb1-R in the diglycosyl moiety.
There are no detectable differences in profile of glycosylation and truncation between PrP Wt and PrP
V180I expressed in cultured cells
To determine whether the PrP V180I mutation is directly responsible for the altered glycosylation and proteolytic profiles observed in fCJD V180I , human neuroblastoma (M17) cells transfected with human PrP V180I , PrP
T183A
, or PrP Wt with valine polymorphism at codon 129 were examined by Western blotting and immunofluorescence confocal microscopy. Western blots showed no significant differences in glycosylation and N-terminal truncation profiles between PrP Wt and PrP V180I before and after treatment with PNGase F when probed with 3F4 antibody (Fig.  5A) . As expected [9, 10] , PrP T183A exhibited a dominant mono197 band and a minor unglycosylated PrP band. Neither diglycosylated PrP nor mono181 was observed in PrP
. No PrP res was detected with 3F4 in all three cell lysates treated with PK alone. After treatment with PK plus PNGase F, a faint PK-resistant deglycosylated PrP band migrating at ,20 kDa was observed in the three lysates, while additional undigested full-length PrP was also detected in PrP T183A (Fig. 5A) . In contrast, PrP res was probed in all PrP species treated with PK alone by using 1E4 (Fig. 5B) . As reported previously [7, 10, 11, 18] , while 1E4 exhibits a poor affinity for untreated PrP, it has a higher affinity for PK-treated PrP compared to 3F4. In PrP T183A , a dominant mono197 and a minor unglycosylated PrP but no diglycosylated PrP res were detected, consistent with our previous observations [10, 11] 
PrP
V180I is present in both cell surface and endoplasmic reticulum Using immunofluorescence confocal microscope, while PrP T183A was mainly found in the endoplasmic reticulum (ER) (Fig. 5C) , evidenced by the co-localization of PrP with calnexin, an ER membrane marker protein, most PrP Wt was observed on the cell surface (Fig. 5E) . These results are consistent with previous observations [10, 11] . In contrast, in cells expressing PrP V180I the PrP staining on the cell surface was reduced compared to cells expressing PrP Wt but higher amounts of PrP were colocalized with calnexin in the ER (Fig. 5D ).
Discussion
Five naturally occurring PrP mutations linked to familial prion diseases including D178N, V180I, T183A, F198S, and E200K have reportedly been associated with altered ratios of the three PrP glycoforms. The PrP T183A mutation completely abolishes the first N-glycosylation site, a process that reasonably explains the dramatic decrease or absence of diglycosylated PrP in both PrP C and PrP Sc in the brain and in cultured cells expressing PrP T183A [3, [9] [10] [11] . In contrast, in patients with the PrP V180I mutation adjacent to N181, it is unclear why the absence of diglycosylated PrP species is evident only in the PK-treated PrP res but not in the untreated PrP in the brain [4] .
Because of the close location to N181, the V180I mutation itself was originally suggested as preventing glycosylation at N181 position [19] . However, using the N-linked glycosylation prediction algorithm NetNGlyc 1.0 at http://www.cbs.dtu.dk/services/ NetNGlyc/ [11] , we predicted a decrease in the glycosylation potential value for N181 in PrP V180I compared to PrP Wt (0.597 vs 0.664) while no potential value was predicted for N181 in PrP T183A . The prediction data suggest that although the T183A mutation completely eliminates the N181 glycosylation site, the V180I mutation may merely alter glycan composition at N181, which is consistent with the current experimental data. Moreover, our study with cultured cells revealed that PrP V180I forms PKresistant diglycosylated PrP res upon PK-treatment, similar to PrP
Wt that was observed previously [10, 11] . It is worth noting that ovine PrP V183I , equivalent to human PrP V180I , also formed PK-resistant diglycosylated PrP in Rov cells when challenged with the scrapie strain 127S [20] . whereas cultured cells express only the mutant allele. Therefore, we first hypothesize that the glycoform-selective prion formation pathway observed in the brain involves dominant-negative inhibition caused by the interaction between misfolded and normal PrP molecules. Dominant-negative inhibition has been well documented in a variety of cell and animal models [21] [22] [23] [24] [25] [26] .
Although the mutant alone is convertible in the cultured cells, its conversion is inhibited in the brain. This could be because the interaction of the misfolded PrP caused by the mutation or altered glycans at N181 with its wild-type counterpart may induce a steric hindrance around the PrP N181 region (Fig. 6) . As a result, mono197 and unglycosylated PrP C are converted into PrP Sc , whereas mono181 and diglycosylated PrP C with the steric hindrance are not (Fig. 6) . Our hypothesis may be consistent with the following recent observations. The conformation between the b2 and a2 loop from residues 165 to 175 has been identified as associated with a dominant-negative effect [27] , which is also adjacent to the first N-linked glycosylation site. Upon infection of Rov cells with prion 127S, while each of all five mutants that removed the second glycosylation site could form PrP res , eight of nine mutants that removed the first glycosylated site could not [20] . Furthermore, in response to ME7 strain challenge, Tg mice lacking the first N-linked site on PrP were resistant, whereas mice lacking the second site were fully susceptible [28] . Interestingly, using the serial protein misfolding cyclic amplification technique, Nishina et al. observed that interactions between different PrP C glycoforms control the efficiency of prion formation involving glycan-associated steric hindrance [29] . Using the same method, the Supattapone group further demonstrated that dominant negative inhibition of prion formation requires no protein X or any other accessory cofactor [30] . Therefore, the region from the loop to the first glycosylation site may be more prone to dominantnegative inhibition by the steric effect. In the case of VPSPr, although there is no PrP mutation, a similar aberrant glycosylation at N181 caused by a rare stochastic event may trigger the processes as described above for fCJD V180I . Further investigation on the origin and interaction of alleles and composition of glycans of PrP Sc in the two diseases could address these issues. Alternatively, the discrepancy between these in vitro results and the in vivo findings may suggest that the absence of both diglycosylated and mono181 PrP Sc is not attributable to the mutation itself. This possibility is also supported by our present finding that although VPSPr shows no mutations in the PrP open reading frame, PrP res of VPSPr likewise not only lacks the PKresistant diglycosylated and mono181 species but also shares the same LLEP and the immunoreactivity preference. All these findings suggest that the two diseases bear a similar pathogenetic mechanism and that fCJD V180I is the familial form of VPSPr. It is conceivable that one or more co-factors may be operating in VPSPr and fCJD V180I which may prevent conversion of diglycosylated PrP and mono181 into PrP Sc but trigger conversion of mono197 and unglycosylated PrP to this unique prion strain. There are no reports to date showing that fCJD V180I has been transmitted [31] . Our preliminary study also indicates that the infectivity of PrP Sc from VPSPr seems to be much lower compared to classic sporadic CJD [32, 33] . Although no family history of neurodegenerative disorders has been reported in fCJD V180I cases, eight out of 26 reported VPSPr cases showed a familial history of dementia [7] . Thus, the PrP Sc generated through this peculiar , PrP V180I and PrP Wt (C, D, and E). Immunofluorescence staining of cells using 3F4 for PrP (green) and calnexin for ER (red). Virtually all PrP T183A was colocalized with calnexin (C). PrP V180I was also colocalized with calnexin, but was found on cell surface equally (D). PrP staining was mostly found on the cell surface in cells expressing PrP Wt (E). Scale bars: 25 mM. doi:10.1371/journal.pone.0058786.g005 glycoform-selective process is characterized by the presence of a unique conformation that forms LLEP upon PK-treatment and has low infectivity. The other co-factor(s) and how it (they) selectively alters glycosylation at N181 is yet to be determined.
The striking similarity in the physiochemical and biological properties of prions found in fCJD V180I and VPSPr favors the hypothesis that the two conditions share a similar pathogenetic mechanism although one is associated with mutant PrP and the other is not [34] . It is worth noting that because of the long disease duration, multiple PK-resistant PrP fragments, and variable PKresistance of PrP Sc , VPSPr was once suspected to be the sporadic form of GSS associated with PrP A117V mutation (GSS-A117V) [7] . In the same study, nevertheless, we indeed observed different ratios and immunoreactivity of PrP Sc between VPSPr and GSS-A117V [7] . Clearly, whether VPSPr is the sporadic form of fCJD V180I or GSS-A117V remains to be further determined. It is conceivable that cells and animals expressing human PrP V180I or PrP A117V will provide valid models for addressing the outstanding questions mentioned above.
In conclusion, our findings provide the first evidence based on patient samples that glycosylation has a significant role in the formation, selection, and strain trait of prions in spontaneous prion diseases. These findings are significant not only in enhancing our understanding of the molecular mechanism of prion formation but also in developing new therapeutic strategies for prion diseases. In addition, glycoform-selective process present in prion propagation may also occur in other neurodegenerative proteinopathies, notably those sharing prion-like mechanisms [35, 36] .
Materials and Methods
Subjects and human brain tissues
Nineteen subjects including 10 VPSPr, 6 fCJD V180I , 2 sCJD, and one fCJD T183A cases were examined. All were referred to the National Prion Disease Pathology Surveillance Center (NPDPSC, Cleveland, OH) except for an fCJD V180I case from France [4] , and two fCJD V180I cases from Japan. The six cases with fCJD
V180I
were three Caucasian and three Asian patients. Written consent to use autopsy material for research purposes had been obtained from patients or legal guardians for all samples. Clinical data and relevant hospital records were coded and handled according to the protocols approved by the Ethical Committee and Institutional Review Board of Case Western Reserve University to protect patients' identities. Frozen brain tissues were processed as previously described [7] .
Molecular genetics
The genomic DNA was extracted from frozen brain tissues. The ORF of the PRNP was amplified by the polymerase chain reaction (PCR) and PCR products were subjected to automated sequencing and cloned then sequenced to confirm the mutation and polymorphisms as previously described [7] . Cloning and production of cell lines M-17 human neuroblastoma cells were transfected with the episomal vector pCEP4b containing the coding sequence of a human wild-type or mutant PrP (T183A or V180I) with valine polymorphism at codon 129 using the cationic lipid DOTAP [Roche Applied Science] and prepared as previously described [9] [10] [11] 37] . Cell lysates were prepared as described previously [10, 11] .
Preparation of brain homogenate, S2, and P2 fractions
The 10% (w/v) brain homogenates were prepared in 9 volumes of lysis buffer (10 mM Tris, 150 mM NaCl, 0.5% Nonidet P-40, 0.5% deoxycholate, 5 mM EDTA, pH 7.4) with pestle on ice. When required, brain homogenates were centrifuged at 1,000 g for 10 min at 4uC. In order to prepare S2 and P2 fractions, the supernatants (S1) were further centrifuged at 35,000 rpm (100,000 g) for 1 hour at 4uC. After the ultracentrifugation, the detergentsoluble fraction was recovered in the supernatants (S2) while the detergent-insoluble fraction (P2) was recovered in the pellets that were resuspended in lysis buffer as described [18] .
Specific capture of PrP
Sc by gene 5 protein and immunoprecipitation of PrP by 6H4 antibody
The preparation of gene 5 protein (g5p) conjugated magnetic beads and specific capture of PrP Sc by g5p beads were conducted as previously described [18] . The immunoprecipitation of PrP from brain homogenates and cell lysates by 6H4-conjugated magnetic beads was performed as previously described [16, 18] .
Immunoblotting
Samples treated with or without PK-digestion were resolved on 15% Tris-HCl Criterion (Bio-Rad) as described previously [18] . The following anti-PrP antibodies were used (Fig. S1 ): mouse monoclonal antibody (mAb) 3F4 directed against human PrP residues 106-110 [38, 39] , 1E4 against human PrP residues 97-105 [10, 18] , 6H4 against human PrP144-152 (Prionics AG, Switzerland), V14 recognizing the human PrP185-196 [11] [12] [13] , Pc248 directed against the octarepeat region [12, 40] , and Bar209 anti-mono197 and unglycosylated PrP mAb [12] (Fig. S1) , recognizing a conformational epitope [12] likely involving human PrP168-181, like anti-mono197 PrP mAb V61 [12] .
Immunofluorescence and confocal microscopy
Immunofluorescence staining of PrP in transfected cells expressing PrP Wt , PrP V180I , or PrP T183A was performed as previously described [11] . In brief, the cells were fixed in 4% paraformaldehyde. After blocking with PBST (10% Goat Serum, 2% T-20, 1% Triton X-100), the cells were then incubated with 3F4 (1:10,000) or calnexin (1:1,000) at room temperature, rinsed with PBS, followed with FITC-conjugated goat anti-mouse IgG at 1:1,000 (Sigma, St. Louis, MO) or Alexa Fluor 568-conjugated goat anti-rabbit as secondary antibody. Microscopy was performed using a high-speed Leica SP5 Broadband confocal microscope (Wetzlar, Germany) and HCX PL APO CS 636 oil immersion objective (NA 1.4). Images were acquired and analyzed using Leica Application Suite software. Further analysis for colocalization and correlation was performed using Imaris imaging suite (Bitplane, St. Paul, MN). Figure S1 Schematic diagram of the NMR-derived structure of human PrP (1) and the epitopes of antiPrP antibodies used in this study. The five black five-point stars represent the octapeptide repeats between residues 51 and 91. The two black right arrows represent the b-sheets. The three black waves represent the a-helical structures. The two black 7-point stars represent the two N-linked glycans at residues 181 and 197. The known epitopes of the five antibodies are indicated including Pc248, 1E4, 3F4, 6H4, and V14. Bar209 has a conformational epitope (12) , which likely involves PrP168-181 as it recognizes PrP C depending on N181 occupancy, like V61 mAb (12) . (TIF) 
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